Mangoceuticals, Inc. (NASDAQ: MGRX) announced on February 6, 2025, significant progress in its ongoing H1N1 efficacy study. The study, conducted by Vipragen Biosciences, focuses on the company's patented respiratory illness prevention technology.
Phase 1 studies have shown a significant reduction in viral load, indicating positive early results for the technology. This advancement underscores the potential of Mangoceuticals' antiviral compound.
The company has also engaged Vipragen Biosciences to structure an H5N1 cohort for expanded research. This move broadens the scope of its antiviral research to address avian influenza, a critical area of global health concern.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.